315P - Correlation between the expression of heat shock proteins and the prognosis of advanced ovarian serous adenocarcinoma
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Ovarian Cancer
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585|
Heat shock protein (HSP) family is overexpressed in many malignant tumors, which plays an important role in drug resistance and prognosis. The present study is aimed to screen the prognosis-related HSP expression in serous ovarian cancers and to evaluate the association between it's expression and survival in ovarian serous adenocarcinoma (AOSC).
HSPs were tested in ovarian cancer specimens by Western Blot in order to detect the candidate proteins whose expressed differently in platium-sensitive and resistent AOSC tumors. Paraffin-embedded tissues from 202 AOSC patients who underwent the primary debulking surgery from 2003 to 2013 were transferred to tissue microarray in which the cadidate HSPs were evaluated by Immunohistochemical analysis.
HSP90AB1 and TRAP1 were determined as the candidate proteins. In general, HSP90AB1 had high expression rate of 59.9% (121/202) and TRAP1 had low expression of 36.6% (74/202). There was no significant correlation between HSP90AB1 expression and clinicopathological factors while TRAP1 expression was correlated with platinum-resistance and preoperative CA125 levels (P = 0.05, 0.034) and weak correlation with other clinicopathological factors. Univariate analysis demonstrated that patients with high HSP90AB1 expression had poor prognosis with worse overallsurvival(OS), progression-free survival(PFS) and treatment-free interval(TFI) as compared to those with low expression (P = 0.003,0.029,0.032, respectively). Patients with high TRAP1 expression had better prognosis in OS, PFS and TFI (P
HSP90AB1, TRAP1 expression are strong prognostic factors in AOSC, which high HSP90AB1 expression level indicates poor prognosis and high TRAP1 expression level indicates good prognosis.
Clinical trial indentification
This is not a clinical trial.
Legal entity responsible for the study
Cancer Institute & Hospital, Chinese Academy of Medical Science and Peking Union Medical College
China National Center for Biotechnology Development
All authors have declared no conflicts of interest.